EUCTR2011-000388-28-DE进行中（未招募）不适用
Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma - VBDD
niversity Medical Center Freiburg0 个研究点开始时间: 2011年4月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient has voluntarily agreed to participate, understands and voluntarily signed a written informed consent form
- •2.Male or female patients with age =18 years without upper age limit
- •3.Patients with refractory or relapsed MM after at least first-line chemotherapy (CTx) or PBSCT (autologous and allogeneic SCT). All lines of relapse are eligible.
- •4.Measurable disease, defined as any quantifiable serum M-protein value OR in light-chain-MM elevated measurable serum free light chains OR in non-secretory MM measurable disease in terms of extramedullary sites and/or Bone marrow (BM) plasmocytosis >10%, 24-h-urine M-protein
- •5.Non-secretory disease allowed, provided magnetic resonance imaging (MRI) or positron emission tomography (PET) or computed tomography (CT) scan can accurately measure at least one plasmocytoma lesion and/or BM-plasmocytosis allows to determine response
- •6.Patient must be at least 30 days from prior CTx, radiation therapy, biological therapy, immunotherapy, major surgery or any other investigational anticancer therapy prior to the first dose of study drugs.
- •7.KPS =60%
- •8.Normal serum potassium and magnesium
- •9.Adequate BM function (ANC =1000/mm3, platelet count =50.000/mm3, Hb >7 g/dl, unless myelosuppression is secondary to BM plasmocytosis >70% involvement)
- •10.Adequate hepatic and renal function (AST and ALT =2.5 times ULN, Bilirubin =1.5 times ULN, eGFR >20 ml/min)
- •11.Patient is able to swallow pills/oral medication
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1.Patient has had prior treatment with Vorinostat or HDAC inhibitors
- •2.Patient has previously been unable to tolerate prior treatment with Bortezomib, Doxorubicin (or other anthracyclines) or Dexamethasone, or has a known hypersensitivity to any components of Bortezomib, Doxorubicin, Vorinostat or Dexamethasone
- •3.Previous treatment above maximum cumulative doses of doxorubicin (> 550mg/m2), daunorubicin (> 550mg/m2), epirubicin (> 900mg/m2), idarubicin (> 120mg/m2), and/or other anthracyclines.
- •4.Patients with severe hepatic impairment or acute diffuse infiltrative pulmonary and pericardial disease, or any of the following: marked myelosuppression; pre-existing heart disease (severe heart failure (ejection fraction [EF]< 30%); acute or history of myocardial infarction, severe arrhythmias, acute inflammatory cardiac disease), inflammation of mucous membranes, hemorrhagic diathesis, established generalised infections.
- •5.Patients with other active severe illness, including patient is known to be Human Immunodeficiency Virus (HIV) positive or has clinically active Hepatitis B or C.
- •6.Patient has preexisting NCI CTC =grade 3 neuropathy.
- •7.Patient with known CNS MM-involvement and/or MM-related/induced meningitis
- •8.Concomitant use of any other investigational drug or participation in a clinical trial within the last thirty days before the start of this study, previous participation in this study
- •9.Known or persistent abuse of medication, drugs or alcohol
- •10.In case of a patient without legal capacity who is unable to understand the nature, significance and consequences of the study, a legal representative has to give and sign the patient informed consent form.
- •11.Persons who are in a relationship of dependence/employment with the sponsor or the investigator
- •12.Female patients with current or planned pregnancy or during nursing period
- •13.Fertile patients refusing to use safe contraceptive methods (at least two) during the study until six months after the final administration of the study medication (for details see clinical trial protocol section 5.3).
研究者
相似试验
已完成
1 期
Safety of Vorinostat in combination with Bortezomib, Doxorubicin andDexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma.A phase I/II studyC90.0Multiple myelomaDRKS00003074niversitätsklinikum Freiburg- vertreten durch den Leitenden Ärztlichen Direktor - Prof. Dr. Dr. h.c. J. R. Siewert34
已完成
1 期
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)Multiple Myeloma in RelapseNCT01394354University Hospital Freiburg34
进行中（未招募）
不适用
A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes - GFM-VOR-2007-1EUCTR2007-002212-26-FRGroupe Francophone des Myélodysplasies
进行中（未招募）
1 期
EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTSMultiple myelomaEUCTR2019-002626-67-ESInstitut Català d'Oncologia360
已完成
1 期
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaChildhood Burkitt LymphomaChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaChildhood MedulloepitheliomaChildhood MeningiomaChildhood Mixed GliomaChildhood Nasal Type Extranodal NK/T-cell LymphomaChildhood OligodendrogliomaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00994500National Cancer Institute (NCI)20